Next Article in Journal
Impact of Microscopic Confirmation on Therapeutic Management of Pancreatic Cancer Patients: Lessons from an Italian Regional Tumor Registry
Previous Article in Journal
A Clinical Outcome of the Anti-PD-1 Therapy of Melanoma in Polish Patients Is Mediated by Population-Specific Gut Microbiome Composition
Previous Article in Special Issue
Effects of Metformin as Add-On Therapy against Glioblastoma: An Old Medicine for Novel Oncology Therapeutics
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Godugu et al. Anti-Cancer Activities of Thyrointegrin αvβ3 Antagonist Mono- and Bis-Triazole Tetraiodothyroacetic Acid Conjugated via Polyethylene Glycols in Glioblastoma. Cancers 2021, 13, 2780

The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY 12208, USA
*
Author to whom correspondence should be addressed.
Cancers 2022, 14(21), 5371; https://doi.org/10.3390/cancers14215371
Submission received: 29 August 2022 / Accepted: 27 September 2022 / Published: 31 October 2022
(This article belongs to the Special Issue Novel Treatment Strategies for Glioblastoma)

Error in Figure

In the original publication [1], there was a mistake in the representative image for bFGF + Compound 3. Specifically, in Figure 5A, there were unintentional mistakes in incorporating representative CAM images from other archived files. The correct image for this panel, along with another PBS control representative image from the same TAT file, is included in the corrected figure. The authors apologize for this unintentional mistake. The changes in the representative images in Figure 5A do not affect the conclusions regarding the biological activity of the compounds studied, as shown in Figure 5B. The images shown are representative single randomly selected images for illustration of the general anti-angiogenesis efficacy of the Tetrac Triazole-PEG conjugated products, and are not for quantitative purposes (5A). The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Corrected Figure 5:

Cancers 14 05371 i001

Reference

  1. Godugu, K.; Rajabi, M.; Mousa, S.A. Anti-Cancer Activities of Thyrointegrin αvβ3 Antagonist Mono- and Bis-Triazole Tetraiodothyroacetic Acid Conjugated via Polyethylene Glycols in Glioblastoma. Cancers 2021, 13, 2780. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Godugu, K.; Rajabi, M.; Mousa, S.A. Correction: Godugu et al. Anti-Cancer Activities of Thyrointegrin αvβ3 Antagonist Mono- and Bis-Triazole Tetraiodothyroacetic Acid Conjugated via Polyethylene Glycols in Glioblastoma. Cancers 2021, 13, 2780. Cancers 2022, 14, 5371. https://doi.org/10.3390/cancers14215371

AMA Style

Godugu K, Rajabi M, Mousa SA. Correction: Godugu et al. Anti-Cancer Activities of Thyrointegrin αvβ3 Antagonist Mono- and Bis-Triazole Tetraiodothyroacetic Acid Conjugated via Polyethylene Glycols in Glioblastoma. Cancers 2021, 13, 2780. Cancers. 2022; 14(21):5371. https://doi.org/10.3390/cancers14215371

Chicago/Turabian Style

Godugu, Kavitha, Mehdi Rajabi, and Shaker A. Mousa. 2022. "Correction: Godugu et al. Anti-Cancer Activities of Thyrointegrin αvβ3 Antagonist Mono- and Bis-Triazole Tetraiodothyroacetic Acid Conjugated via Polyethylene Glycols in Glioblastoma. Cancers 2021, 13, 2780" Cancers 14, no. 21: 5371. https://doi.org/10.3390/cancers14215371

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop